Business Context and Reporting Period
This Form 8-K was filed by BioSig Technologies, Inc. (BSGM) on April 8, 2020. The report details a material definitive agreement entered into by the company's majority-owned subsidiary, ViralClear Pharmaceuticals, Inc., with the Mayo Foundation for Medical Education and Research.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures. The only quantifiable financial data disclosed relates to the transaction terms:
- Equity Issuance: ViralClear issued 259,959 shares of its common stock to Mayo.
- Future Obligations: The agreement includes earned royalty payments and certain milestone payments contingent on future sales.
Material Changes
The primary material change is the execution of a know-how license agreement on April 8, 2020. Key terms include:
- Exclusive License: ViralClear received an exclusive worldwide license (with sublicense rights) to patent rights for anti-viral agents targeting COVID-19.
- Non-Exclusive License: ViralClear received a non-exclusive worldwide license to use Mayo's know-how necessary for product development.
- Duration: The agreement expires on the later of the licensed patent rights' expiration or the 7th anniversary of the first commercial sale of a Licensed Product.
Outlook, Risks, and Contingencies
Management commentary is limited to the description of the agreement. The filing outlines specific termination contingencies where Mayo may end the agreement early:
- Failure by ViralClear to cure a material breach.
- Commencement of legal action by ViralClear or a sublicensee against Mayo (excluding actions for uncured material breaches by Mayo).
- Insolvency of ViralClear.
Investor Verification Checklist
- Verify the fair market value of the 259,959 shares of ViralClear common stock issued to Mayo.
- Confirm the specific dollar amounts or calculation formulas for the "earned royalty payments" and "milestone payments."
- Review the scope of the "patent rights" and "know-how" licensed to ensure they cover the intended COVID-19 therapeutic applications.
- Assess the financial impact of the equity issuance on BioSig Technologies' consolidated balance sheet.